Skip to main content
. Author manuscript; available in PMC: 2019 Jan 1.
Published in final edited form as: Pharmacogenet Genomics. 2018 Jan;28(1):7–16. doi: 10.1097/FPC.0000000000000317

Table 5.

Five-SNP phased diplotypes predicted in treatment-seeking smokers in PNAT trial

Diplotype Group
#
Full Diplotype N in PNAT CYP2A6 activity
(nicotine metabolite ratio, NMR),
mean of diplotype group
Corresponding
liver bank
diplotype group
Reference G T T T A / G T T T A 41 0.3 Reference Group

1 G C C G G / G C C G G 110 0.55 1
2 G T T T A / G C C G G 123 0.40 2
3 G T T G A / G C C G G 43 0.46 3
4 G C C G A / G C C G G 55 0.55 4
5 G T T T A / G T T G A 20 0.38 5

6 G C C G G / A C C G G 38 0.49 6
7 G T T T A / A C C G G 29 0.42 7
8 G T T T A / G C C G A 30 0.43 8
9 G T T G A / G C C G A 8 0.42 9
10 G T T G A / A C C G G 8 0.54 10
11 G C C G A / A C C G G 10 0.54 11
12 G T T T A / G C C T G 5 0.48 13
13 A C C G G / A C C G G 3 0.45 14
14 G C C G A / G C C G A 11 0.41 15
15 G T C G G / G C C G G 2 0.21 22
16 G C T G G / G C C G G 23 0.54 N/A
17 G T T T A / G C T G G 13 0.45 N/A
18 G C C G G / A C T G G 12 0.46 N/A
19 G T T G G / G C C G G 11 0.46 N/A
20 G C C T G / G C C G G 10 0.60 N/A
21 G C C G A / A C T G G 6 0.51 N/A
22 G C T G G / G C C G A 5 0.54 N/A
23 G C T T G / G C C G G 4 0.67 N/A
24 G T T T A / G C T G A 4 0.45 N/A
25 G T T G A / G T T G G 2 0.35 N/A
26 G T T T A / G T T G G 2 0.33 N/A
27 G C C T G / A C C G G 1 0.69 N/A
28 G T T G G / A C C G G 1 0.35 N/A
29 A C T G G / A C T G G 1 0.46 N/A
30 G T T T A / A C T G G 1 0.53 N/A
31 G C C T G / G C C G A 1 0.67 N/A
32 G C C T G / G C C T G 1 0.30 N/A
33 G C T T G / G C C T G 1 0.48 N/A
34 G C T G A / G C T G A 1 0.61 N/A
35 G C T G G / G C T G G 1 0.54 N/A
36 G T T G A / G C T G G 1 0.43 N/A
37 G T T G G / G C T G G 1 0.33 N/A
38 G T T T A / G C T T G 1 0.36 N/A
39 G T T T A / G T C G A 1 0.22 N/A
a

. Full reference diplotype is bolded